risk stratification
Hackensack Meridien Health Launches Cancer Risk, Early Detection Program; Eyes Multi-Cancer Testing
Premium
Patients will be offered germline genetic testing after an assessment that includes genetic, lifestyle, and other clinical risk factor analysis.
UK's NICE Expands Tumor Profiling Recommendations for Guiding Adjuvant Chemo in Early Breast Cancer
Previously, NICE recommended EndoPredict, Prosigna, and Oncotype DX for node-negative breast cancer only, but the new guidance includes lymph node-positive disease.
Agendia's ImPrint Headed for Prospective Validation as Tool for Guiding Breast Cancer Immunotherapy
Premium
Retrospective data in two breast cancer subtypes have shown the test's ability to identify responders to neoadjuvant immunotherapy with chemo.
PreciseDx Partners With UCLA to Study Cancer Recurrence Risk Assay in TNBC
The researchers will evaluate the ability of the PreciseBreast assay to assess recurrence risk in triple-negative breast cancer patients.
Trial Failure Raises Questions About MRD Testing Utility, but Prognostic Evidence Remains Strong
Presentations at last week's ASCO GI meeting highlighted the ongoing generation of promising data for ctDNA-based minimal residual disease testing despite recent missteps.